Weekly Spotlight - 31.10.24

Community

We want to hear your story!

Fill in the form to share your experiences and any challenges you’ve faced living with your condition, for a chance to be featured in one of our weekly newsletters!

In the News

CAR T-Cell Therapies Show Promise in Treating Aggressive Blood Cancers

CAR T-cell therapies are making waves in treating blood cancers like lymphoma and myeloma. By reengineering patients' T-cells to target cancer, these therapies show promise in achieving remission. While side effects like cytokine release syndrome need managing, the future looks bright for these innovative treatments.

Circulating Tumour DNA in Non-Hodgkin Lymphoma Surveillance

Circulating tumour DNA (ctDNA) is the new detective in town for non-Hodgkin lymphomas, offering a noninvasive alternative to traditional biopsies. With high detection rates and concordance with tissue samples, ctDNA is proving to be a promising tool for disease monitoring.

Prognostic Role of SM-like Genes in Mantle Cell Lymphoma Survival

For mantle cell lymphoma, SM-like genes are the new stars. These RNA-binding proteins, especially LSM1 and LSM8, are linked to poor survival outcomes. Their over-expression might be the cause of cell division and RNA splicing.

NVG-111 Trial for Lymphoma and Leukaemia Safety and Efficacy Testing

The NVG-111 trial is testing a new treatment for relapsed or stubborn blood cancers like chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL). It's a phase 1 trial, so safety is the main focus. Involvement could help future patients. Trials are in London and Manchester.